This week, J&J JNJ filed for voluntary bankruptcy for the third time in an attempt to bring an end to thousands of lawsuits ...

The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.

Beyond acquisitions, we continue to expect steady future dividends, supported by a payout ratio of close to 50% relative to adjusted earnings per share. Patents, economies of scale, and a powerful ...

美国 FDA 肿瘤药咨询专家委员会于 9 月 26 日以 10 票赞成、2 票反对、1 票弃权的投票结果，决定默沙东的 Keytruda（帕博利珠单抗）和百时美施贵宝（BMS）的 Opdivo（纳武利尤单抗）作为一线治疗药对于生物标志物 PD-L1 检测呈阴性的胃癌患者无效。这一投票结果符合专家会成员、FDA 审评人员和申办人的共识，即当 PD-L1 ...

Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top ...

An FDA expert panel on Thursday voted against a broader use of Merck (MRK) and Bristol-Myers (BMY) immune checkpoint inhibitors Keytruda and Opdivo. Read more here.

The days of broad stomach cancer labels for PD-1 inhibitors appear to be numbered.  | The days of broad stomach cancer labels ...

We recently compiled a list of the 7 Cheap Beginner Stocks to Invest In. In this article, we will look at where Merck & Co., ...

During clinical trials, Bristol Myers Squibb's KarXT was said to offer better treatment with fewer side effects. Meanwhile, Pfizer's sickle cell disease treatment Oxbryta was withdrawn from all ...

Summit ...

The ODAC will weigh risk-benefit analyses from the FDA and sponsors on Keytruda, Opdivo, and Tevimbra when given with chemo in all comers and in PD-L1-positive subgroups.

Merck said on Wednesday its therapy did not meet the main goal of a late-stage trial evaluating it in patients with a type of ...